Good MorningInvestor confidence was rattled on Tuesday when word of not one but two trials of COVID-19 vaccines was halted due to “adverse” events. The news triggered an early morning sell-off that had the major indices down about -0.50% when the opening bell sounded. While concerning, the news was largely shrugged off in favor of earnings from JP Morgan Chase and Citigroup. The nation’s two largest consumer banks reported better than expected results that foreshadow what could be a market-moving earnings season.
Revenue at both JP Morgan and Citigroup fell on a YOY period but came in above the consensus estimates. The most noteworthy detail in either report is that reserve-builds for credit losses were less than expected. In light of the current conditions, the slowdown in reserve-build was taken as a vote of confidence in the economic recovery. If the rest of the financial sector reports in like fashion a new all-time high is in store for the S&P 500.
Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Markets | |
Sometimes a company issues positive news and its stock price inexplicably goes down. Investors that take advantage of these situations can come out ahead when the market catches up with reality.
Last week GenMark Diagnostics (NASDAQ:GNMK) provided better than expected revenue guidance and announc... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Retail/Wholesale | |
A Golden-Age For Fastenal?
I’ve heard (read I should say) that current conditions are a “golden age” for homebuilders. Pent-up demand, low inventory, streamlined businesses, and low-interest rates are combining in a way that means sustained, healthy business for the home builder... Read the Full Story |
|
Finance | | JPMorgan Chase & Co Is A Buy After Reporting Q3 Result
After reviewing the JPMorgan Chase & Co (NYSE:JPM) calendar Q3 earnings report and looking at the chart I cannot believe this stock is still trading at such a low valuation. Trading at only 17X this year’s consensus and 12X next i... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Medical | |
Admittedly, things weren't looking good for AstraZeneca (LON:AZN) for a while there. With good reason, too; its vaccine trials were stopped dead in their tracks when some truly disastrous side effects started showing up, and that might well have knocked the company out of the COVID-19 recovery sta... Read the Full Story |
|
Retail/Wholesale | | The Upgrades Are Already Rolling In For Levi Strauss
Levi Strauss (NYSE:LEVI) reported earnings about a week ago and blew away the consensus. The company proved that established brands with a healthy eCommerce presence are well-positioned for the pandemic. The company saw its revenue fall nearly 27... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Technology | | Semiconductor equipment maker Kulicke and Soffa Industries (NASDAQ: KLIC) stock is an overlooked play on the surge in future semiconductor demand. Shares have underperformed the S&P 500 index (NYSEARCA: SPY) as peers are shaping up for a breakout. There’s no question the demand for semicon... Read the Full Story |
|
Technology | | The used car market has been very strong since the onset of the pandemic. There are several reasons for this strength, but a big piece of the puzzle has been a low new vehicle inventory. Automakers were forced to temporarily shut down for a couple of months earlier this year, which forced people tha... Read the Full Story |
|
Technology | | Cybersecurity firm CyberArk Software (NASDAQ: CYBR) shares have awoken but still trading below its pre-COVID levels in February. Shares are underperforming the benchmark S&P 500 index (NYSEARCA: SPY) and momentum peers in the cybersecurity space. Rather than chase the newcomers, prudent investor... Read the Full Story |
|
Technology | |
Whether you’re just beginning your journey as an investor with limited capital or you simply enjoy hunting for affordable stocks that can turn into lucrative investments, seeking out strong businesses that don’t have a hefty price tag can be a solid strategy. The truth is that you can ... Read the Full Story |
|
Technology | |
The business world moves at light speed these days. Many companies that once were known as industry leaders have had to adapt to new trends or face becoming irrelevant in the eyes of investors. Take IBM (NYSE:IBM) for example. It’s a business that was once the gold standard in the Informatio... Read the Full Story |
|
The Early Bird Stock Of The Day CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California. | | View Today's Stock Pick |
|
